Cutera (NASDAQ:CUTR) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cutera (NASDAQ:CUTR) in a research report released on Saturday. The firm issued a sell rating on the medical device company’s stock.

Cutera Stock Performance

Shares of Cutera stock opened at $0.35 on Friday. Cutera has a 52 week low of $0.28 and a 52 week high of $4.97. The stock has a market capitalization of $7.02 million, a price-to-earnings ratio of -0.05 and a beta of 1.26. The firm has a fifty day moving average of $0.43 and a two-hundred day moving average of $0.83.

Hedge Funds Weigh In On Cutera

Institutional investors have recently modified their holdings of the stock. Ground Swell Capital LLC bought a new position in Cutera during the 2nd quarter worth approximately $37,000. Squarepoint Ops LLC grew its holdings in shares of Cutera by 164.5% in the 2nd quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after buying an additional 70,870 shares during the period. Finally, Bank of Montreal Can raised its stake in Cutera by 14.2% during the 2nd quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock worth $455,000 after buying an additional 35,248 shares during the period. 90.70% of the stock is currently owned by institutional investors and hedge funds.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.